Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Urothelial cancer: Less gained from immunotherapy in patients with poor performance scores

Publish date:: December 26, 2019

Key clinical point: Immune checkpoint inhibitors may not overcome the unfavorable prognostic influence of poor performance status in patients with advanced urothelial cancer.

Major finding: Overall survival with immune checkpoint inhibitor therapy was better for patients with a performance status of 0 or 1 vs. at least 2 treated in the first line (median, 15.2 vs. 7.2 months; HR, 0.62; P = .01) although not in subsequent lines (median, 9.8 vs. 8.2 months; HR, 0.78; P = .27).

Study details: Multicenter retrospective cohort study of 499 patients given immune checkpoint inhibitors for advanced urothelial cancer.

Disclosures: Dr. Khaki did not disclose any conflicts of interest. The study was supported by the National Cancer Institute, the National Center for Advancing Translational Sciences of the National Institutes of Health, the Seattle Translational Tumor Research Program at the Fred Hutchinson Cancer Research Center, the Imperial Experimental Cancer Medicine Centre, the Cancer Research UK Imperial Centre, the Wellcome Trust Strategic Fund, and Merck.

Citation:

Khaki AR et al. Cancer. 2019 Dec 12. doi: 10.1002/cncr.32645.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,